The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://bookmark-template.com/story26691017/retatrutide-vs-tirzepatide-a-comparative-analysis